Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Several late-stage pipeline products have the potential to address some of these unmet needs
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Subscribe To Our Newsletter & Stay Updated
